----
Current ValuationThe current P/E ratio is -0.71, within the reasonable range, cheaper than 94.25% of the time in the past 1 years, and the industry ranks 92/255, the industry Median -1.30.
-0.706xP/E
--Stock price
-0.706xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.71x
- Typical range
- -0.71x–-0.69x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -54.76x | 148.12% | $57.18B |
BAYZFUSBayer Aktiengesellschaft | -24.60x | -- | $49.64B |
BAYRYUSBayer | -24.19x | -- | $48.81B |
VTRSUSViatris | -49.05x | 107.75% | $20.15B |
ELANUSElanco Animal Health | -56.44x | 129.36% | $11.23B |
AXSMUSAxsome Therap | -47.65x | 26.61% | $9.13B |
VREOFUSVIREO GROWTH INC | -129.50x | -- | $8.69B |
CURLFUSCuraleaf Holdings, Inc. | -146.98x | -- | $7.65B |
BLTEUSBelite Bio | -61.22x | 29.87% | $6.27B |
DFTXUSDefinium Therapeutics | -13.53x | 53.61% | $4.79B |
MANEUSVeraDermics | -43.65x | 97.44% | $4.55B |
EWTXUSEdgewise Therapeutics | -22.04x | 137.29% | $4.35B |
RGCUSRegencell Bioscience | -516.66x | -- | $3.64B |
AMLXUSAmylyx Pharmaceuticals | -23.14x | 1.76% | $3.52B |
TARSUSTarsus Pharmaceuticals | -69.98x | 205.82% | $3.25B |
ELVNUSEnliven Therapeutics | -29.32x | 6.39% | $3.11B |
MBXUSMBX Biosciences | -26.28x | 31.12% | $2.74B |
SUPNUSSupernus Pharma | -22.66x | 70.59% | $2.49B |
BHCUSBausch Health | -2.05x | 307.94% | $2.25B |
PHVSUSPharvaris BV | -11.01x | 10.70% | $2.18B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
